- Home
- RDI vs CALC Comparison
RDI vs CALC Comparison
Compare RDI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- CALC
- Stock Information
- Founded
- RDI 1937
- CALC 2011
- Country
- RDI United States
- CALC United States
- Employees
- RDI N/A
- CALC N/A
- Industry
- RDI Movies/Entertainment
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- CALC Health Care
- Exchange
- RDI Nasdaq
- CALC Nasdaq
- Market Cap
- RDI 27.9M
- CALC 32.4M
- IPO Year
- RDI N/A
- CALC N/A
- Fundamental
- Price
- RDI $1.34
- CALC $3.80
- Analyst Decision
- RDI
- CALC Strong Buy
- Analyst Count
- RDI 0
- CALC 2
- Target Price
- RDI N/A
- CALC $14.50
- AVG Volume (30 Days)
- RDI 30.6K
- CALC 132.0K
- Earning Date
- RDI 08-13-2025
- CALC 08-11-2025
- Dividend Yield
- RDI N/A
- CALC N/A
- EPS Growth
- RDI N/A
- CALC N/A
- EPS
- RDI N/A
- CALC N/A
- Revenue
- RDI $205,644,000.00
- CALC N/A
- Revenue This Year
- RDI $7.47
- CALC N/A
- Revenue Next Year
- RDI $13.22
- CALC N/A
- P/E Ratio
- RDI N/A
- CALC N/A
- Revenue Growth
- RDI N/A
- CALC N/A
- 52 Week Low
- RDI $1.17
- CALC $1.42
- 52 Week High
- RDI $1.89
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- RDI 50.85
- CALC 73.90
- Support Level
- RDI $1.29
- CALC $3.37
- Resistance Level
- RDI $1.34
- CALC $4.26
- Average True Range (ATR)
- RDI 0.06
- CALC 0.41
- MACD
- RDI 0.01
- CALC 0.21
- Stochastic Oscillator
- RDI 49.52
- CALC 82.80
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.